(VIANEWS) – Shares of Bergenbio (GI: BGBIO.OL) have experienced an astonishing 28.34% gain over the last 10 sessions, rising from kr0.09 to kr0.12 as of 15:50 EST Tuesday afternoon – this growth follows two straight sessions of gains for Bergenbio and its Oslo Bors Benchmark Index constituents – as it continued its upward trajectory by increasing by 0.27% on Tuesday and reaching 1,250.22 for its second day running.
Bergenbio’s recent performance is truly impressive, as evidenced by its stock’s final close at kr0.12 representing a 99.06% discount from its 52-week high of kr13.03. However, investors appear optimistic about Bergenbio’s prospects and have driven its value up significantly over the past week.
Be mindful of past performance as it cannot guarantee future returns; investors should carefully consider all relevant factors before making investment decisions. Yet the recent increase in Bergenbio stock price suggests investors are optimistic about its potential growth and success on the market.
About BERGENBIO
BerGenBio ASA is a clinical-stage biopharmaceutical company focused on creating novel medicines to treat immune-evasive, drug-resistant, and metastatic cancers as well as respiratory conditions. Bemcentinib, their flagship oral once-daily inhibitor of AXL receptor tyrosine kinase, is currently being evaluated in Phase 1b/2a clinical trials for non-small cell lung cancer, acute myeloid leukemia and COVID-19. Bemcentinib is currently being researched as a possible treatment option for glioblastoma, 2L non-small cell lung cancer, melanoma, pancreatic cancer and mesothelioma. BerGenBio ASA currently is conducting Phase 1b clinical trials of Tilvestamab, an anti-AXL function-blocking monoclonal antibody, for treating ovarian cancer, while Mipasetamab Uzoptirine has begun Phase 1 trials against solid tumors. BerGenBio has an agreement with Merck & Co for clinical trials collaboration; established in 2007 and with headquarters in Bergen Norway.
Yearly Analysis
Based on the information available, Bergenbio stock is currently trading significantly below its 52-week high of kr13.03 but considerably above its 52-week low of kr0.08; this could indicate either that its valuation may be under or overstated depending on an investor’s perspective.
Negative EBITDA of -2.91 indicates that the company is operating at a loss. While this may cause investors to worry, as it suggests the business isn’t currently generating enough revenue to cover expenses, negative EBITDA doesn’t always signal financial distress; some companies may incur high research and development expenses to foster long-term growth.
Before investing, investors must carefully evaluate Bergenbio’s current financial performance as well as potential risks and opportunities associated with investing in it. Additional research may help to gain a clearer understanding of its health and prospects for growth.
Technical Analysis
BERGENBIO stock has experienced a noticeable decrease in value recently, falling below both its 50-day and 200-day moving averages. Furthermore, its reported volume of 53271659 represents significantly increased trading activity.
Looking at volatility, BERGENBIO’s intraday variation average for the past week, month and quarter was negative 0.45%, positive 0.91% and positive 6.38%, respectively. It had its highest average amplitude last week at 10.39% while during month/quarter it peaked at 5.73%/6.38% respectively.
According to the stochastic oscillator, BERGENBIO stock is currently considered oversold (=20), suggesting that now could be an optimal time for investors to buy it. Before taking any investment decisions however, investors must conduct comprehensive research before making their final decision.
Equity Analysis
BerGenBio’s trailing 12-month earnings per share (EPS) stands at kr-2.83, suggesting it has suffered losses in its recent history.
Return on Equity (ROE) of the company over its 12-month trailing period is negative -179.58%, suggesting it has failed to generate enough profits to compensate its shareholders adequately and this may cause concern for potential investors.
Investors should carefully consider these financial metrics and other relevant factors before making investment decisions. Conduct additional research, analysis and consultation with an experienced financial advisor prior to making any definitive investment decisions.
More news about BERGENBIO (BGBIO.OL).
